BIIB

SEC source: 0001127602-20-005776 · form4.xml · derivative · entry 13

Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,562

Underlying: Common Stock · 420 shares

Expires 2022-02-12

F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-20-005776 · form4.xml · derivative · entry 12

Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,982

Underlying: Common Stock · 358 shares

Expires 2022-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-20-005776 · form4.xml · derivative · entry 11

Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 608

Underlying: Common Stock · 294 shares

Expires 2021-02-12

F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-20-005776 · form4.xml · derivative · entry 10

Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 902

Underlying: Common Stock · 312 shares

Expires 2021-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-20-005776 · form4.xml · derivative · entry 9

Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 484 shares

Expires 2020-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date.

SEC source: 0001127602-20-005776 · form4.xml · derivative · entry 8

Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,780

Underlying: Common Stock · 6,780 shares

Expires 2023-02-12

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-20-005776 · form4.xml · nonDerivative · entry 6

Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,231.264

SEC source: 0001127602-20-005776 · form4.xml · nonDerivative · entry 5

Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,337.264

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-005776 · form4.xml · nonDerivative · entry 4

Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,979.264

SEC source: 0001127602-20-005776 · form4.xml · nonDerivative · entry 3

Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,071.264

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-005776 · form4.xml · nonDerivative · entry 2

Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,759.264

SEC source: 0001127602-20-005776 · form4.xml · nonDerivative · entry 1

Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,912.264

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-005773 · form4.xml · derivative · entry 5

CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,348

Underlying: Common Stock · 2,253 shares

Expires 2022-02-12

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-20-005773 · form4.xml · derivative · entry 4

CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,601

Underlying: Common Stock · 1,919 shares

Expires 2022-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-20-005773 · form4.xml · derivative · entry 3

CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,550

Underlying: Common Stock · 10,550 shares

Expires 2023-02-12

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-20-005773 · form4.xml · nonDerivative · entry 2

CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,118

SEC source: 0001127602-20-005773 · form4.xml · nonDerivative · entry 1

CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,732

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-005771 · form4.xml · derivative · entry 9

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,680

Underlying: Common Stock · 37,680 shares

Expires 2023-02-12

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-20-005771 · form4.xml · derivative · entry 8

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,048

Underlying: Common Stock · 6,762 shares

Expires 2022-02-12

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-20-005771 · form4.xml · derivative · entry 7

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,810

Underlying: Common Stock · 5,760 shares

Expires 2022-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-20-005771 · form4.xml · derivative · entry 6

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,112

Underlying: Common Stock · 5,870 shares

Expires 2021-02-12

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-20-005771 · form4.xml · derivative · entry 5

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,982

Underlying: Common Stock · 6,234 shares

Expires 2021-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-20-005771 · form4.xml · nonDerivative · entry 4

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,928.321

SEC source: 0001127602-20-005771 · form4.xml · nonDerivative · entry 3

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,483.321

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-005771 · form4.xml · nonDerivative · entry 2

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,723.321

SEC source: 0001127602-20-005771 · form4.xml · nonDerivative · entry 1

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,063.321

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-001123 · form4.xml · derivative · entry 4

CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,996

Underlying: Common Stock · 1,690 shares

Expires 2021-01-02

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-20-001123 · form4.xml · derivative · entry 3

CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,686

Underlying: Common Stock · 1,302 shares

Expires 2021-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-20-001123 · form4.xml · nonDerivative · entry 2

CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,813

SEC source: 0001127602-20-001123 · form4.xml · nonDerivative · entry 1

CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,219

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-034363 · form4.xml · derivative · entry 4

Kramer Robin · CIK 0001609222 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 354

Underlying: Common Stock · 92 shares

Expires 2021-12-03

F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-034363 · form4.xml · derivative · entry 3

Kramer Robin · CIK 0001609222 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 446

Underlying: Common Stock · 84 shares

Expires 2021-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-034363 · form4.xml · nonDerivative · entry 2

Kramer Robin · CIK 0001609222 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150.481

SEC source: 0001127602-19-034363 · form4.xml · nonDerivative · entry 1

Kramer Robin · CIK 0001609222 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175.481

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 51.685 shares acquired under the Biogen Inc. employee stock purchase plan on 3/29/2019.

F2 · balance_after: Includes 39.796 shares acquired under the Biogen Inc. employee stock purchase plan on 6/28/2019.

SEC source: 0001127602-19-034175 · form4.xml · nonDerivative · entry 1

Posner Brian S · CIK 0001372455 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,995

F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

SEC source: 0001127602-19-034176 · form4.xml · derivative · entry 5

Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,174

Underlying: Common Stock · 625 shares

Expires 2020-12-01

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-19-034176 · form4.xml · derivative · entry 4

Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,799

Underlying: Common Stock · 543 shares

Expires 2020-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-19-034176 · form4.xml · nonDerivative · entry 3

Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,695

SEC source: 0001127602-19-034176 · form4.xml · nonDerivative · entry 2

Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,855

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-034176 · form4.xml · nonDerivative · entry 1

Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,312

SEC source: 0001127602-20-004705 · form5.xml · nonDerivative · entry 3

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,594

SEC source: 0001127602-20-004705 · form5.xml · nonDerivative · entry 2

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,594

SEC source: 0001127602-20-004705 · form5.xml · nonDerivative · entry 1

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,594

SEC source: 0001127602-19-026026 · form4.xml · derivative · entry 5

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 428

Underlying: Common Stock · 247 shares

Expires 2020-08-01

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-19-026026 · form4.xml · derivative · entry 4

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 675

Underlying: Common Stock · 179 shares

Expires 2020-08-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-19-026026 · form4.xml · nonDerivative · entry 3

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,215

SEC source: 0001127602-19-026026 · form4.xml · nonDerivative · entry 2

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-026026 · form4.xml · nonDerivative · entry 1

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,116

SEC source: 0001127602-19-024060 · form4.xml · derivative · entry 4

Karp Daniel · CIK 0001744046 · EVP, Corporate Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,174

Underlying: Common Stock · 390 shares

Expires 2021-07-02

F4 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-19-024060 · form4.xml · derivative · entry 3

Karp Daniel · CIK 0001744046 · EVP, Corporate Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,564

Underlying: Common Stock · 196 shares

Expires 2021-07-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).